Clinical Trial Update: A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity [Phase 3]

View source ↗

Summary

Phase 3 open-label, single-dose study assessing safety and efficacy of GSK1358820 (botulinum toxin type A) for post-stroke focal upper limb spasticity in Chines…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-stroke Spasticity

Drugs mentioned

• GSK1358820

Snippet

Sponsor: GlaxoSmithKline | Conditions: Spasticity, Post-Stroke | Phase 3 | Status: COMPLETED | Results posted: 2012-09-24